Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2More about Open Access at the Crick
Authors listLewis Au Annika Fendler Scott TC Shepherd Karolina Rzeniewicz Maddalena Cerrone Fiona Byrne Eleanor Carlyle Kim Edmonds Lyra Del Rosario John Shon Winston A Haynes Barry Ward Ben Shum William Gordon Camille L Gerard Wenyi Xie Nalinie Joharatnam-Hogan Kate Young Lisa Pickering Andrew JS Furness James Larkin Ruth Harvey George Kassiotis Sonia Gandhi Crick COVID-19 Consortium Charles Swanton Charlotte Fribbens Katalin Wilkinson Robert Wilkinson David K Lau Susana Banerjee Naureen Starling Ian Chau CAPTURE Consortium Samra Turajlic
Toggle all authors (35)
Patients with cancer are currently prioritized in coronavirus disease 2019 (COVID-19) vaccination programs globally, which includes administration of mRNA vaccines. Cytokine release syndrome (CRS) has not been reported with mRNA vaccines and is an extremely rare immune-related adverse event of immune checkpoint inhibitors. We present a case of CRS that occurred 5 d after vaccination with BTN162b2 (tozinameran)-the Pfizer-BioNTech mRNA COVID-19 vaccine-in a patient with colorectal cancer on long-standing anti-PD-1 monotherapy. The CRS was evidenced by raised inflammatory markers, thrombocytopenia, elevated cytokine levels (IFN-γ/IL-2R/IL-18/IL-16/IL-10) and steroid responsiveness. The close temporal association of vaccination and diagnosis of CRS in this case suggests that CRS was a vaccine-related adverse event; with anti-PD1 blockade as a potential contributor. Overall, further prospective pharmacovigillence data are needed in patients with cancer, but the benefit-risk profile remains strongly in favor of COVID-19 vaccination in this population.
Journal Nature Medicine
Issue number 8